• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } Biotech (General)

SBIR/STTR WORKSHOP – NIH FOCUSED

UPCOMING: SBIR/STTR WORKSHOP – NIH FOCUSED Wednesday January 17 & Thursday January 18, 2018 (1.5 days)  Long Island High Technology Incubator Hosted by the Center for Biotechnology* with support from Empire State Division of Science, Technology and Innovation (NYSTAR) The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) SBIR/STTR programs award over…

2018 CRC Guide Now out!

The CRC’s Guide to Coordinating Clinical Research, Third Edition The CRC’s Guide to Coordinating Clinical Research, 3rd edition, is the most comprehensive, easy-to-read training guide for novice and experienced clinical research coordinators. The newly-released third edition includes industry facts, insights on the role and responsibilities, personal experiences to learn from, checklists to help you be…

Q Therapeutics and REPROCELL Partnering on Stem Cell-based Therapies for ALS

Q Therapeutics of the United States and REPROCELL of Japan are teaming up to develop stem cell-based therapies for central nervous system diseases such as ALS and transverse myelitis, or TM. The collaboration will meld Q Therapeutics’ expertise in nerve cell therapy with REPROCELL’s expertise in stem cell treatments. “This collaboration with Q Therapeutics and their scientific co-founder, Dr….

Neurologist Talks About Diagnosing ALS

Neurologist Dr. Elijah Stommel explains that he sees two newly diagnosed ALS patients each week and that each case is unique. In Andy’s case, the first indications of the disease appeared in his limbs. Andy had the genetic form of the disease and both of his siblings passed away from ALS. Dr. Stommel explains that ALS…

BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 20, 2017 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held on January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California.   more at: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2323496

IQVIA: new article out “Heralding the Era of Human Data Science”

IQVIA, the recently formed merger of IMS Health and Quintiles, just announced publication of ““Heralding the Era of Human Data Science”.   “Human Data Science is a revolutionary new way to harness advances in technology, analytics and, above all, human ingenuity to help you pursue improvements in health outcomes.” More at:  https://www.iqvia.com/~/media/IQVIA/PDFS/AccessPoint/A1-from-IQVIA-AccessPoint-14-ORB1824_F.pdf  

Why We Should Talk to Patients Who Drop Out of Clinical Trials

Dec 13, 2017 By Sandy Chase Applied Clinical Trials Like so many of my colleagues in the world of clinical patient recruitment and retention, I spend a lot of time contemplating data points. Key performance indicators. Screen fail rates. Randomization numbers. Retention rates (and their dubious sibling, drop-out rates). I’ve learned that data points which surface predictably in recap decks, often paint an unfinished picture. Of all…

Tagged

Cancer immunotherapy may work better in patients with specific genes

Date:December 15, 2017 Source:Columbia University Medical Center Summary:Investigators have been trying to understand why and have recently found how an individual’s own genes can play a role in the response to the immunotherapy drugs. Cancer cells arise when DNA is mutated, and these cells should be recognized as “foreign” by the immune system. However, cancer…

Dana-Farber Cancer Institute CEO Wants To Tax Biopharma To Pay For The NIH

Dr. Laurie Glimcher, President and CEO of the Dana-Faber Cancer Institute (DFCI), is justifiably concerned that Congress is not providing sufficient funding for the NIH. She expressed her worries last week at the Forbes Healthcare Summit in NYC saying that “places like the DFCI are where new drugs are born” and that “decreased funding to…

NurOwn, Now in Phase 3 Trial, Shows Potential in ALS Patients with Rapid Progression, BrainStorm’s CMO Says in Interview

BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND meeting held in Boston last week. Both these findings and an ongoing Phase 3 trial, now recruiting patients in the U.S., were discussed in greater detail with Ralph…